EICHORCondition: Major Depressive Disorder · Sponsor: Sirtsei Pharmaceuticals, Inc.
This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| IMA Clinical Research | Phoenix, Arizona, United States | — |
| Noble Clinical Research | Tucson, Arizona, United States | — |
| SanRo Clinical Research Group | Bryant, Arkansas, United States | — |
| Clinical Innovations | Bellflower, California, United States | — |
| Sun Valley Research Center | Imperial, California, United States | — |
| Synergy San Diego | Lemon Grove, California, United States | — |
| Excell Research | Oceanside, California, United States | — |
| CiTrials | Riverside, California, United States | — |
| Collaborative Neuroscience Research | Torrance, California, United States | — |
| Sunwise Clinical Research | Walnut Creek, California, United States | — |
| Next Level Clinical Trials | West Covina, California, United States | — |
| MCB Clinical Research Centers | Colorado Springs, Colorado, United States | — |
+ 38 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06254612